CHICAGO, IL / ACCESSWIRE / February 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ: COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that Taglich Brothers, Inc. ("Taglich Brothers") has initiated coverage of the Company's common stock.

The coverage and associated reports will be available at www.taglichbrothers.com.

Founded in 1991, Taglich Brothers is a full-service broker dealer with an exclusive focus on microcap companies, defined as those having a market capitalization of less than $250 million. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "We are pleased that Taglich Brothers has initiated coverage of our common stock. A great deal has occurred at Cosmos, which we believe has not yet been reflected in our current valuation. Over the past year, we have accomplished multiple milestones, including transforming our balance sheet, completing strategic acquisitions such as Cana and Cloudscreen, enhancing our production facilities, launching new brands, filing patent applications for our R&D products, and establishing a comprehensive portfolio of generic drugs. Our efforts are already yielding positive results. In this context, we believe that receiving thorough coverage from analysts will help raise awareness within the investment community and ultimately showcase the intrinsic value of our assets."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Chicago, Illinois, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, and www.zipdoctor.co, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Disclaimer

All research issued by Taglich Brothers is based on public information. The Company does not undertake the responsibility to advise you of changes in figures or in their views. The Company pays a fee of $3,000 per month for 12 months for research coverage, which includes the creation and dissemination of research reports. This is not a solicitation of any order to buy or sell. Taglich Brothers, fully disclosed with its clearing firm, Axos Clearing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. There is no guarantee that the target price for the stock will be met or that the predicted business results for the Company will occur. There may be instances when fundamental, technical, and quantitative opinions contained in Taglich Brothers' reports are not in concert. Taglich Brothers does not currently have an Investment Banking relationship with the Company and was not a manager or co-manager of any offering for the Company within the last three years.

Investor Relations
Paul Lampoutis
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, N.Y. 10169
Tel.: (212) 661-7566
Fax: (212) 661-7526
E-Mail: Cosmoshealth@capitallink.com

SOURCE: Cosmos Health Inc.